EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study

Uwe Pleyer iD, Salem Al-Mutairi, Conor C Murphy iD, Rola Hamam, Shereen Hammad, Orsolya Nagy, Zsuzsanna Szepessy, Yan Guex-Crosier iD, Karina Julian, Zohar Habot-Wilner, Sofia Androudi iD

British Journal of Ophthalmology · 2023

DOI: 10.1136/bjo-2021-320770 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Ophthalmology, 2023. Verfasst von Uwe Pleyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Charité Universitätsmedizin Berlin, Berlin, Germany uwe.pleyer@charite.de. Hauptthemen laut MEDLINE: Panuveitis, Uveitis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim This study evaluated real-life adalimumab impact in patients with active non-infectious intermediate, posterior, or panuveitis (NIIPPU).

Methods

Adults with active NIIPPU received adalimumab in this prospective, observational study (06/2017–04/2020). Patients were evaluated at baseline (V0) and four follow-up visits over 12 months (V1–V4). Primary endpoint: proportion of patients achieving quiescence (anterior chamber (AC) cells grade and vitreous haze (VH) grade≤0.5+ in both eyes, no new active chorioretinal lesions) at any follow-up visit. Secondary endpoints: proportion of patients achieving quiescence at each visit; proportion of patients maintaining response; and proportion of patients with flares. Workability, visual function, healthcare resource utilisation, and safety were evaluated.

Results

Full analysis set included 149 patients. Quiescence at any follow-up visit was achieved by 129/141 (91%) patients. Quiescence at individual visits was achieved by 99/145 (68%), 110/142 (77%), 102/131 (78%), and 99/128 (77%) patients at V1–V4, respectively. Number of patients in corticosteroid-free quiescence increased from 51/147 (35%; V1) to 67/128 (52%; V4; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PanuveitisUveitisAdultHumansAdalimumabQuality of LifeProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

inflammation

Substanzen

Adalimumab

Autor:innen und Institutionen

  • Charité Universitätsmedizin Berlin, Berlin, Germany uwe.pleyer@charite.de.
  • Al-Bahar Ophthalmology Center - Al-Sabah Hospital, Kuwait City, Kuwait.
  • Ophthalmology, Royal Victoria Eye an Ear Hospital, Dublin, Ireland.
  • American University of Beirut, Beirut, Lebanon.
  • AbbVie Biopharmaceuticals GmbH, Dubai, UAE.
  • AbbVie Inc, North Chicago, Illinois, USA.

ORCID-Profile: Uwe Pleyer, Conor C Murphy, Yan Guex-Crosier, Sofia Androudi

Förderung

  • AbbVie

Zitieren

APA

Pleyer, U., Al-Mutairi, S., Murphy, C. C., Hamam, R., Hammad, S., Nagy, O., Szepessy, Z., Guex-Crosier, Y., Julian, K., Habot-Wilner, Z., & Androudi, S. (2023). Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study. British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2021-320770

Vancouver

Pleyer U, Al-Mutairi S, Murphy CC, Hamam R, Hammad S, Nagy O, et al. Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study. British Journal of Ophthalmology. 2023. doi:10.1136/bjo-2021-320770

BibTeX
@article{Pleyer2023,
  author = {Pleyer, Uwe and Al-Mutairi, Salem and Murphy, Conor C and Hamam, Rola and Hammad, Shereen and Nagy, Orsolya and Szepessy, Zsuzsanna and Guex-Crosier, Yan and Julian, Karina and Habot-Wilner, Zohar and Androudi, Sofia},
  title = {Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study},
  journal = {British Journal of Ophthalmology},
  year = {2023},
  doi = {10.1136/bjo-2021-320770}
}
Kostenlos starten →